18 April 2024
18 April 2024
The deal will now see IGM doubling down on IgM antibody development for immunology and inflammation targets.
LX2006 consists of adeno-associated virus (AAV) vector carrying the frataxin gene, responsible for causing Friedreich’s ataxia.
Ultimovacs also plans to implement operational prioritisation to extend its financial runway into Q4 2025.
The acquisition of the CNS drug for Alzheimer's will enhance Essential's product portfolio and global market reach.
Preventing cyberattacks before they happen will not only protect hospitals but also lower IT costs, saving money for what are often cash-strapped institutions.
Clearmind is focused on the discovery and development of new psychedelic-derived therapeutics to manage health issues.
Theolytics will use the £19m funding to progress THEO-260 into clinical trials for ovarian cancer.
The financial injection was provided by venture capital entities M Ventures and MP Healthcare Venture Management.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
